Day: October 24, 2022

ROME, Oct. 24, 2022 (GLOBE NEWSWIRE) — Luiss Rector Andrea Prencipe received the Journal of Business Venturing’s Best Paper Award for the paper “The Language of Investments: How Language-Structure Influences Crowdfunding Investments.” The study was conducted with Professors Francesca Di Pietro, University Milano Bicocca, Francesca Masciarelli, University G. d’Annunzio Pescara, and Vangelis Souitaris, Cass Business School. It explores how language can predict individuals’ investment choices and their propensity for entrepreneurship. The study relies on the assumption that language predicts people’s investment behaviour and entrepreneurial propensity. Languages are divided into those that rarely distinguish present and future time (such as German, Dutch, Swedish, and Chinese, i.e., weak-future languages, and those that have a marked distinction between present and future time such as French, Italian and English, i.e., strong-future languages. Speakers of weak-future languages appear to perceive future events as closer than do speakers of strong-future languages. Speakers of weak-future languages are likely attracted to the idea of personally investing in entrepreneurial ventures, including crowdfunding investments. By linking language, culture, cognitive frames and economic behaviours, the study adds an important and interdisciplinary explanation for cross-country variation in early-stage crowdfunding investment, and our findings have important practical implications for entrepreneurs, crowdfunding investors, and policymakers.

This important award confirms that in Luiss the education model combines academic rigour but, at the same time, practical relevance. «Our faculty comprises academic professors and practitioners from the real world – meaning executives, diplomats, representatives from public administration», said Luiss University Dean, Andrea Prencipe. Rome’s Luiss University is revered for both its physical beauty and educational excellence, blending its rich history with the digital age of the present to prepare students that shape the future. Throughout its four departments of Economics and Finance, Business and Management, Law and Political Science, the private university offers an innovative educational approach which is gaining increasing international recognition.

«In Luiss students will have the opportunity to grow their mindset. They will have the opportunity to acquire tools that will enable them to face the complexity and the discontinuities of the challenges that they will face once they will enter the job market. Those challenges, as we know, are increasingly complex, often more discontinuous. So a change in the mindset is fundamental and our programs do that», said Prencipe.

For more information:

LaPresse SpA Communication and Press Office Director
Barbara Sanicola – barbara.sanicola@lapresse.it

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/60095220-e2c0-46ed-a26d-b4679f8f8fd2

The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.

GlobeNewswire Distribution ID 8680988

FcResolv NOG Models Provide Greater Clarity and More Translatable Data

RENSSELAER, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing drug discovery animal model solutions, has launched the FcResolv NOG portfolio, the first and only super immunodeficient mouse models lacking residual murine Fc gamma receptors (FcγRs) known to confound results in antibody-based therapy studies.

Murine FcγRs can cause false positives or false negatives, leading to incorrect conclusions and derail drug discovery. FcResolv NOG models knock out these receptors for greater clarity in antibody-based drug studies, affording investigators greater confidence and more translatable data with fewer studies and fewer animals. With applicability in oncology, immuno-oncology, and autoimmune disease, FcResolv NOG models are suitable for engrafting a wide range of human cells and tissues, including simultaneous human tumor engraftment and immune system humanization.

“Antibody-based therapies represent one of the fastest-growing classes of drugs, creating a pressing need for better preclinical tools to assess therapeutics such as monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies,” said Dr. Michael Seiler, vice president of commercial products at Taconic. “Taconic’s FcResolv NOG portfolio enables researchers to evaluate drug candidates like these on their own merits, free of interference from residual murine Fc gamma receptor activity.”

FcResolv NOG models eliminate the false negatives that occur when an antibody-based therapeutic’s Fc domain interacts with murine FcγRs as well as the false positives that result when FcγRs trigger residual murine immune activity. They also eliminate costly deconvolution steps otherwise needed to distinguish true drug efficacy from off-target effects mediated through the mouse immune system. With more reliable answers, researchers can target their drug discovery investments more strategically and effectively.

The FcResolv NOG model portfolio is based on the super immunodeficient CIEA NOG mouse^®. The portfolio currently includes two models:

• FcResolv NOG, for tumor xenografts using cell lines or patient-derived tumors, engraftment of other normal or pathological human cells and tissues, and immune system humanization studies
• FcResolv hIL-15 NOG, which supports engraftment of human NK cells and is suitable for efficacy studies on antibody-based therapeutics with an antibody-dependent cellular cytotoxicity (ADCC) mechanism of action

To learn more about the FcResolv NOG portfolio, visit www.Taconic.com/fcresolv. Or call 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email info@taconic.com.

About Taconic Biosciences, Inc.

Taconic Biosciences is a fully licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom-generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immuno-oncology mouse models, and integrated model design and breeding services, Taconic operates service laboratories and breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.

Media Contact:

Louise Baskin, Senior Director New Product Pipeline

303-432-2495

Louise.Baskin@taconic.com

PASADENA, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) — Innova Medical Group, Inc. (“Innova”), a global leader in antigen testing, announced that it has received from the United States Food and Drug Administration (“FDA”) a letter formally closing out the Warning Letter originally sent to the company on June 10, 2021.

This close-out letter was received following an on-site FDA field inspection where FDA reviewed, among other things, Innova’s remediation of the concerns raised in the Warning Letter.  The evidence presented to FDA during the inspection demonstrated that Innova had successfully addressed the Warning Letter. The inspection was successfully completed with no observations and no Form 483.

Dr. Charles Huang, Founder and CEO of Innova Medical Group Inc, said: “Innova Medical Group is committed to complying with all legal and regulatory requirements anywhere it operates or conducts business.  Now, with FDA’s Warning Letter behind us, Innova will focus its efforts in executing its mission of bringing innovative medical products to as many people as possible in the most efficient and effective manner.”

About Innova Medical Group Inc.

Innova Medical Group is a global health screening and diagnostic innovator driven to dramatically improve health outcomes worldwide with equitable, high-value testing solutions. Its strategic and iterative approach is to create, build, deploy and distribute a wide array of innovative, accessible tests customized to meet and empower the user at their respective point of need. www.innovamedgroup.com

Contact Information:
Sunny Sun
Head of Group Communications
sunny.sun@pasacacapital.com
6264608488

This content was issued through the press release distribution service at Newswire.com.

GlobeNewswire Distribution ID 8680587

TALLINN, Estonia, Oct. 24, 2022 (GLOBE NEWSWIRE) — Eurora Solutions, the provider of a leading AI/ML (artificial intelligence/machine learning) backed cross-border trade compliance platform, launches a partnership with DPDgroup, one of the world’s leading parcel delivery network. 

This partnership will enable DPDgroup, which delivers 2.1 billion parcels yearly, to enhance its quality and compliance processes whilst lowering the costs of customs processing.

DPDgroup will use Eurora’s AI/ML-backed platform to automate the allocation of product classification (HS) codes and compliance with the export control rules applied in the European Union, the United Kingdom, and the United States. The allocation of product classification (HS) codes and export control classification (ECCN code) is a pivotal step within the export process, as these classifications are needed to prove all restrictions and license requirements have been duly checked by the shipper before exporting an item.

Eurora’s compliance platform processes up to 5,000 requests per second with 98% accuracy* – the highest level of accuracy, speed, and automation available in the market. As there are more than 15,000 10-digit commodity codes in the EU alone, it is impossible to match this speed and cost with manual or hybrid methods, most used today.

As a next step, both companies are looking towards extending the geographical coverage of export compliance services, namely to the Middle East and Asia.

“Eurora and the DPDgroup have been closely working together since the beginning of 2022 to elaborate the rules of different jurisdictions, containing a wide range of classification rules and restrictions that have been ´learned´ by the Eurora machine,” said Marko Lastik, founder and Group CEO of Eurora.

DPDgroup, delivering over 8.4 million parcels worldwide each day, was looking for a solution that would enhance its parcel delivery operations. “In a context where product safety and transport security processes are key, and with growing international activity, we always aim to enhance quality and compliance. Using AI and Machine Learning solutions will help us improve the scalability and reliability of our international operations, while paving the path for future opportunities like new customer services, new geography, and further automation,” said Olivier Tsalpatouros, Senior Director Regulatory & Global Trade Affairs at DPDgroup.

“Years of scientific research and developing machine learning capabilities have allowed Eurora to demonstrate that we are trusted by the logistics and postal industry. Eurora AI engine can find the most appropriate response from a large amount of data by learning from constantly adding data,” Marko Lastik explained.

Eurora’s AI uses over 500 million records of training data from real transactions of the world’s largest logistics service providers. The platform can be used by online sellers, marketplaces, logistics and postal companies to automate tax and duty declarations and assign the appropriate HS code.

*Level observed on Eurora’s overall compliance platforms solutions in 2022.

Photos: Please use the link here to access photos, videos and logos of DPD and Eurora co-operation.

About GeoPost/DPDgroup

DPDgroup is one of the world leading parcel delivery networks, aiming to be a reference in sustainable delivery and become a leading enabler of e-commerce acceleration. We combine innovative technology and local knowledge to provide a flexible and user-friendly service for both shippers and shoppers.

With 120,000 delivery experts operating in nearly 50 countries, and a network of 70,000 Pickup points, DPDgroup delivers 8.4 million parcels worldwide each day – 2.1 billion parcels per year – through the brands DPD, Chronopost, SEUR, BRT and Jadlog. DPDgroup is the parcel delivery network of GeoPost. GeoPost posted sales of €14.7 billion in 2021.

About Eurora Solutions

Eurora uses artificial intelligence and machine learning to automatically manage cross-border VAT, duty amounts, and declarations.

In recent months, Eurora has opened a UK Central office in London and a US Central office in Miami. Chris Lentjes, a Pitney Bowes and DHL veteran with more than 20+ years of industry experience, became Eurora’s US CEO; e-commerce heavyweight Walter Trezek joined Eurora as the Non-Executive Chairman of the Supervisory Board.

Eurora was founded in 2018 by Marko Lastik, a global logistics expert with over 30 years of experience, most of it connected with Asia. Eurora employs over 165 people in 18 countries.

For more information:
Mari-Liis Kitter
Press Contact pr@eurora.com

GlobeNewswire Distribution ID 1000752544

NEW YORK, Oct. 24, 2022 (GLOBE NEWSWIRE) — In conjunction with the start of the 2022-23 National Hockey League (NHL) season, Sportradar (NASDAQ: SRAD) and the NHL introduced a refreshed NHL.TV, the League’s direct-to-consumer international OTT subscription service, available to hockey fans in certain countries and territories outside of the U.S. and Canada, to provide an engaging and fan-friendly viewing experience of live and on-demand NHL games.

Sportradar is delivering its award-winning OTT solution to help the NHL manage the end-to-end workflow of NHL.TV, including the OTT backend, all OTT frontend applications (including web and mobile applications) and UX/UI design, as well as third-party integrations on the platform.  The revamped NHL.TV is available in more than 120 countries and territories around the world.

In addition to live game streams, NHL.TV offers fans team-specific personalization features, including on-demand videos and additional highlights. NHL.TV will be available on connected TV applications including Android and Fire TV and is also deployed on the Foxxum Operating System.

“Today’s sports fans expect a viewing experience that is highly personalized and tailored to their unique interests. By utilizing our truly dynamic and trusted data-driven, end-to-end OTT solution, which have been developed and refined over the last 15 years, NHL.TV has the ability to meet and exceed viewer demands,” said Ed Blonk, Chief Commercial Officer at Sportradar. “We look forward to working closely with the NHL to deliver an innovative product that will deepen fan engagement now and in the future.”

“Similar to our North American fan base, NHL international fans are extremely tech savvy and expect a premium digital viewing experience,” said Stephen McArdle, NHL Senior Executive Vice President, Digital Media & Strategic Planning. “Sportradar’s refresh of NHL.TV for certain international markets will help provide fans around the world with a more personalized and enhanced experience with the game, and we look forward to continuing to collaborate with Sportradar to deliver a best-in-class international direct-to-consumer platform.”

Through a landmark, global 10-year agreement announced in June 2021, Sportradar is the NHL’s Official Betting Data Rights, Official Betting Streaming Rights and Official Media Data Rights Partner, distributing the League’s official data and statistics to media, technology and sports betting companies worldwide, including real-time data from NHL EDGE, the League’s Puck and Player Tracking technology, and live streams of NHL games via betting operators’ digital betting platforms available in legalized markets. Additionally, as an Official Integrity Partner of the NHL, Sportradar proactively helps to safeguard the integrity of the NHL’s competitions by monitoring global gaming activity and trends worldwide.

To learn more about Sportradar’s OTT solutions, please visit: https://sportradar.us/sports-media/ott/.

ABOUT SPORTRADAR

Sportradar is the leading global sports technology company creating immersive experiences for sports fans and bettors. Established in 2001, the company is well-positioned at the intersection of the sports, media and betting industries, providing sports federations, news media, consumer platforms and sports betting operators with a range of solutions to help grow their business. Sportradar employs more than 3,500 full-time employees in 20 countries worldwide. It is our commitment to excellent service, quality and reliability that makes Sportradar the trusted partner of more than 1,700 customers in over 120 countries and an official partner of the NBA, NHL, MLB, NASCAR, UEFA, FIFA, ICC and ITF. Sportradar covers over 890,000 events annually across 92 sports. With deep industry relationships, Sportradar is not just redefining the sports fan experience; it also safeguards sports through its Integrity Services offerings across the world.  www.sportradar.com

About the NHL
The National Hockey League (NHL®), founded in 1917, consists of 32 Member Clubs. Each team roster reflects the League’s international makeup with players from more than 20 countries represented, all vying for the most cherished and historic trophy in professional sports – the Stanley Cup®. Every year, the NHL entertains more than 670 million fans in-arena and through its partners on national television and radio; more than 191 million followers – league, team and player accounts combined – across Facebook, Twitter, Instagram, Snapchat, TikTok, and YouTube; and more than 100 million fans online at NHL.com. The League broadcasts games in more than 160 countries and territories through its rightsholders including ESPN, Turner Sports and NHL NetworkMC in the U.S.; Sportsnet and TVA Sports in Canada; Viaplay in the Nordic Region; and CCTV and Tencent in China; and reaches fans worldwide with games available to stream in every country. Fans are engaged across the League’s digital assets on mobile devices via the free NHL® App; across nine social media platforms; on SiriusXM NHL Network Radio; and on NHL.com, available in eight languages and featuring unprecedented access to player and team statistics as well as every regular-season and playoff game box score dating back to the League’s inception, powered by SAP. NHL Original Productions and NHL Studios produce compelling original programming featuring unprecedented access to players, coaches and League and team personnel for distribution across the NHL’s social and digital platforms.

The NHL is committed to building healthy and vibrant communities using the sport of hockey to celebrate fans of every race, color, religion, national origin, gender identity, age, sexual orientation, and socio-economic status. The NHL’s Hockey Is For Everyone initiative reinforces that the official policy of the sport is one of inclusion on the ice, in locker rooms, boardrooms and stands. The NHL is expanding access and opportunity for people of all backgrounds and abilities to play hockey, fostering more inclusive environments and growing the game through a greater diversity of participants. To date, the NHL has invested more than $100 million in youth hockey and grassroots programs, with a commitment to invest an additional $5 million for diversity and inclusion programs over the next year.

Source: Sportradar Group AG

Media:
Sandra Lee
comms@sportradar.com

Brad Klein
bklein@nhl.com

Investor Relations:
Christin Armacost
investor.relations@sportradar.com

First joint research project between Sanofi and the BioMed X Institute, co-creation of a next-generation virtual patient engine for clinical translation of drug candidates

HEIDELBERG, Germany, Oct. 24, 2022 (GLOBE NEWSWIRE) — BioMed X announced today the launch of their first joint research project with Sanofi. As part of this, a new research group to be established at the BioMed X Institute in Heidelberg, Germany, will focus on the development of a versatile computational platform able to accurately predict the efficacy of first-in-class drug candidates in virtual patient populations.

The research collaboration will address one of the most important bottlenecks of the pharmaceutical industry today: a 90% failure rate of new drug candidates during clinical development. It is the aim to transform the practice of medicine with the use of digital data and artificial intelligence, and thus, this project will benefit from Sanofi’s deep datasets and expertise. As a proof-of-concept, the initial model will focus on chronic immune-mediated diseases such as atopic dermatitis (AD) and inflammatory bowel disease (IBD).

“In the past two years, we have gained significant experience in the field of artificial intelligence through our strategic partnership with AION Labs in Israel. Our new collaboration with Sanofi allows us to further extend our data science and AI expertise in Heidelberg, where we have developed an ideal incubation environment for biomedical innovation at the interface between academia and industry,” explains Christian Tidona, Founder and Managing Director of the BioMed X Institute.

“Identifying quality clinical candidates for treatment of patients with unmet need is among the most rewarding parts of the research and development process,” said Frank Nestle, Global Head of Research and Chief Scientific Officer at Sanofi. “This groundbreaking research collaboration will allow us to partner with scientists with unique computational skills and diverse capabilities that will help us to achieve our goals of bringing vital treatments to patients with chronic inflammatory diseases. This collaboration will be instrumental for advancing with our core mission of transforming drug discovery and development through application of AI-based modeling and simulation.”

A diverse team of talented early-career scientists tackling this challenge will be jointly selected by the two companies through the successful and unique recruiting model designed by BioMed X, which entails a global call for application followed by a five-day innovation boot camp. The winning team will be hosted for up to five years by the BioMed X Institute, which is embedded in the life sciences campus of the University of Heidelberg, less than an hour away from Sanofi’s Research & Development site in Frankfurt.

The new team will join the 11 research groups at the BioMed X Institute already working with complex human ex-vivo models and data science in oncology, immunology, and neuroscience.

Interested candidates who want to drive this research team are invited to respond to this international call for applications and submit a project proposal via the BioMed X Career Space at https://bio.mx/career before Jan. 8, 2023.

About BioMed X

BioMed X is an independent research institute located on the campus of the University of Heidelberg in Germany, with a world-wide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world’s brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds – academia and industry – and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.

Contact Information:
Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706

Related Images

Image 1: BioMed X Logo

BioMed X Logo

Image 2: Virtual Patient

Virtual Patient

This content was issued through the press release distribution service at Newswire.com.

Attachment

• BioMed X Logo

GlobeNewswire Distribution ID 8680523